The estimated Net Worth of Zsolt Harsanyi is at least 3.13 百万$ dollars as of 1 June 2024. Zsolt Harsanyi owns over 88 units of Emergent Biosolutions Inc stock worth over 2,120$ and over the last 18 years he sold EBS stock worth over 2,742,135$. In addition, he makes 385,000$ as Independent Director at Emergent Biosolutions Inc.
Sign up
Zsolt Harsanyi EBS stock SEC Form 4 insiders trading
Zsolt has made over 16 trades of the Emergent Biosolutions Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 88 units of EBS stock worth 666$ on 1 June 2024.
The largest trade he's ever made was buying 50,000 units of Emergent Biosolutions Inc stock on 7 June 2019 worth over 39,000$. On average, Zsolt trades about 3,998 units every 95 days since 2006. As of 1 June 2024 he still owns at least 280 units of Emergent Biosolutions Inc stock.
You can see the complete history of Zsolt Harsanyi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Zsolt Harsanyi biography
Dr. Zsolt Harsanyi, Ph.D., is an Independent Director of the Company. Dr. Harsanyi has served as chairman of the board of N-Gene Research Laboratories, Inc., a privately-held biopharmaceutical company, since March 2011. Prior to that, Dr. Harsanyi served as chief executive officer and chairman of the board of directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to February 2011. In January 2016, Dr. Harsanyi returned to Exponential Biotherapies Inc. to serve as chairman of the board. Since August 2016, Dr. Harsanyi has been a director of Aptevo Therapeutics Inc., a publicly-traded biotech company which focuses on bringing novel oncology and hematology therapeutics to market. Dr. Harsanyi served as president of Porton International plc, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was vice president of corporate finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress' Office of Technology Assessment, served as a consultant to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell Medical College. Dr. Harsanyi received a Ph.D. from Albert Einstein College of Medicine and a B.A. from Amherst College. Harsanyi's qualifications to serve on our Board of Directors include his industry experience, including his senior executive and financial positions.
What is the salary of Zsolt Harsanyi?
As the Independent Director of Emergent Biosolutions Inc, the total compensation of Zsolt Harsanyi at Emergent Biosolutions Inc is 385,000$. There are 12 executives at Emergent Biosolutions Inc getting paid more, with Robert Kramer having the highest compensation of 3,693,820$.
How old is Zsolt Harsanyi?
Zsolt Harsanyi is 76, he's been the Independent Director of Emergent Biosolutions Inc since 2004. There are 2 older and 18 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.
What's Zsolt Harsanyi's mailing address?
Zsolt's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Insiders trading at Emergent Biosolutions Inc
Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over 131,382,266$ worth of Emergent Biosolutions Inc stock and bought 4,647 units worth 138,981$ . The most active insiders traders include Seamus Mulligan、Fuad El Hibri、Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of 147,206$. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth 61,100$.
What does Emergent Biosolutions Inc do?
emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent
What does Emergent Biosolutions Inc's logo look like?
Complete history of Zsolt Harsanyi stock trades at Aptevo Therapeutics Inc、Emergent Biosolutions Inc
Emergent Biosolutions Inc executives and stock owners
Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:
-
Robert Kramer,
President, Chief Executive Officer, Director -
Fuad El-Hibri,
Executive Chairman of the Board -
Robert G. Kramer,
CEO, Pres & Exec. Director -
Richard Lindahl,
Chief Financial Officer, Executive Vice President, Treasurer -
Atul Saran,
Executive Vice President, Corporate Development, General Counsel and Corporate Secretary -
Adam Havey,
Executive Vice President - Business Operations -
Fuad El-Hibri,
Founder & Exec. Chairman -
Richard S. Lindahl,
Exec. VP, CFO & Treasurer -
Adam R. Havey,
Exec. VP & COO -
Atul Saran,
Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel -
Seamus Mulligan,
Director -
Ronald Richard,
Lead Independent Director -
Zsolt Harsanyi,
Independent Director -
Louis Sullivan,
Independent Director -
Jerome Hauer,
Independent Director -
George Joulwan,
Independent Director -
Kathryn Zoon,
Independent Director -
Sue Bailey,
Independent Director -
Marvin White,
Director -
Robert Burrows,
Vice President, Investor Relations -
Sean Kirk,
Executive Vice President, Manufacturing and Technical Operations -
Katherine Strei,
Executive Vice President, Human Resources and Communications, Chief Human Resources Officer -
Katherine Strei,
Exec. VP of HR & Chief HR Officer -
Nina DeLorenzo,
Sr. VP of Global Communications & Public Affairs -
Lynn Kieffer,
VP of Corp. Communications -
Howard Anderson,
Sr. VP & Chief Information Officer -
Karen L. Smith,
EVP, Chief Medical Officer -
John Niederhuber,
Director -
Daniel Abdun Nabi,
SVP Corp Aff, GC & Secretary -
L.L.C. Bio Pharm,,
10% owner -
Stephen Lockhart,
SVP Product Development -
L.L.C. Intervac,,
10% owner -
Steven Chatfield,
President, EPD UK & CSO -
R Don Elsey,
VP Finance, CFO & Treasurer -
Barry Labinger,
EVP, Biosciences Div. -
Denise Esposito,
SVP Legal Affairs & GC -
L.L.C. Biologika,,
-
Biologic Products, Inc. Mic...,
-
Kyle Keese,
SVP Mktg & Comm. -
Joe M Allbaugh,
Director -
Mauro Gibellini,
SVP Corporate Dev. -
Investments Ltd Microscience,
10% owner -
Shahzad Malik,
Director -
Edward Arcuri,
EVP & COO -
Thomas Zink,
SVP & CMO -
Robert Calvin Myers,
-
Joseph C Papa,
President and CEO -
Jennifer Lynne Fox,
EVP, Ext Aff, GC, Corp Sec -
Keith Katkin,
Director -
Coleen Glessner,
EVP, Quality & Ethics, and CPL -
Sujata Tyagi Dayal,
Director -
Paul Anthony Williams,
SVP, Products Business -
William Hartzel,
SVP, Bioservices -
Neal Franklin Fowler,
Director -
Donald W De Golyer,
Director